References
[1] Duchartre Y, Bachl S, Kim HN, et al. Effects of CD49d-targeted antisense-oligonucleotide on α4 integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies.PLoS One. 2017;12(11):e0187684. DOI:
10.1371/journal.pone.0187684[2] Limmroth V, Barkhof F, Desem N, Diamond MP, Tachas G; ATL1102 Study Group. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS [published correction appears in Neurology. 2015 Jan 6;84(1):105].Neurology. 2014;83(20):1780-1788. DOI:
10.1212/WNL.0000000000000926
